Global Ophthalmic Drugs Market Forecast 2018-2028 - Visiongain Report

LONDON, July 2, 2018 /PRNewswire/ --

Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs 

The global ophthalmic drugs market [https://www.visiongain.com/report/global-ophthalmic-drugs-market-forecast-2018-2028 ] is expected to grow at a CAGR of 4.4% in the first half of the forecast period. The market is expected to grow at a CAGR of 4.8% from 2017-2028. The market is estimated at $24bn in 2017, dominated by the retinal disorder drugs segment.

(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 298-page report you will receive 123 tables and 113 figures- all unavailable elsewhere.

The 298-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report [https://www.visiongain.com/report/global-ophthalmic-drugs-market-forecast-2018-2028 ] today you stay better informed and ready to act.

Report Scope 

- Global Ophthalmic Drugs market forecasts from 2017-2028

- This report also breaks down the revenue forecasts to 2028 for the global ophthalmic drugs market by the leading submarkets: - Retinal Disorder Drugs - Allergic, Inflammatory & Infective Drugs - Glaucoma Drugs - Dry Eye Drugs - Other Ophthalmic Drugs

- This report includes revenue forecasts to 2028 for the following ophthalmic drugs: - Eylea - Lucentis - Avastin - Visudyne - Jetrea - Pataday - Vigamox - Patanol - TobraDex - Cravit - AzaSite - Acular - Lumigan and Ganfort - Xalatan/Xalacom - Travatan/Travatan Z and DuoTrav - Alphagan/Alphagan P and Combigan - Azopt - Trusopt - Zioptan - Cosopt - Tapros/Taflotan - Restasis - Refresh - Hyalein - Diquas

- This report provides individual revenue forecasts to 2028 for these national markets: - The US - Japan - EU5: Germany, France, the UK, Spain, Italy - Russia - China - India - Brazil - Rest of the World

- Our study provides a SWOT analysis and discusses Porter's Five Forces analysis that influence the global ophthalmic drugs market

- Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

- Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry: - Novartis - Regeneron - Allergan - Roche - Valeant - Santen - Bayer - Pfizer - Senju

Visiongain' [https://www.visiongain.com ]s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Global Ophthalmic Drugs Market Forecast 2018-2028: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/report/global-ophthalmic-drugs-market-forecast-2018-2028

Acucela Actavis Advanced Cell Technologies Aerie Pharmaceuticals Aerpio Therapeutics Alcon Alembic Algeta Alimera Sciences Allegro Allergan Akorn Amakem Amgen Ampio Pharmaceuticals Apotex Asahi Glass AstraZeneca Aurobindo Pharma Ltd Aventis Barr Laboratories Bausch & Lomb Biocad BioDiem Biovail Corporation BioXpress Therapeutics Bristol-Myers Squibb Can-Fite BioPharma  Cipla Chengdu Kanghong Pharmaceutical Chiesi Farmaceutici S.p.A Chiron Corporation Chugai Pharmaceutical CIBA VISION Colby Pharmaceuticals Daiichi Sankyo Eleven Biotherapeutics Eli Lilly ESBATech EyeCyte EyeGate Eyetech Pharmaceuticals ForeSight Biotherapeutics ForSight VISION4 Fougera Pharmaceuticals Gene Signal Genentech GlaxoSmithKline Hospira iCo Therapeutics Icon Bioscience InSite Vision Inspire Pharmaceuticals Instituto Terapeutico Delta Ltda Jenapharm Johnson & Johnson Kala Pharmaceuticals KalVista Kestrel Ophthalmics Kyorin Pharmaceutical Kyowa Hakko Kirin LEO Pharma Lpath MacuCLEAR MacuSight MAP Pharmaceuticals MEAgate International FZLLC Meda Merck & Co. (Merck) MerLion Molecular Partners MSD K.K. Neurim Pharmaceuticals Neurotech Nicox SA NovaBay Novagali Novartis Novel Labs Inc OHR Pharmaceutical Omeros OphthaliX Ophthotech PanOptica Patheon Pharmaceuticals Par Pharmaceutical Pfizer Pharmacia PreCision Dermatology Procter & Gamble pSivida QLT Quark Pharmaceuticals  Regeneron Reckitt Benckiser Roche Roche Consumer Health R-Tech Ueno RXi Pharmaceuticals Salix Sanofi Sandoz Santaris Pharma Santen Schering AG Seikagaku Senju Servier Shire SkinMedica Sobi Stelgerwald Spark Therapeutics Takeda ThromboGenics Upjohn UV North America Valeant Vanda Pharmaceuticals Ventana Medical Systems Warburg Pincus LLC Watson Wockhardt Wyeth Pharmaceuticals Zach System Spa

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

    Photo: 
    http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

SOURCE Visiongain